1
|
Parkins MD, Elborn JS. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronicPseudomonas aeruginosainfection in cystic fibrosis. Expert Rev Respir Med 2014; 5:609-22. [DOI: 10.1586/ers.11.56] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
2
|
Comparative activity of several antimicrobial agents against nosocomial Gram-negative rods isolated across Canada. Can J Infect Dis 2012; 6:76-82. [PMID: 22416207 DOI: 10.1155/1995/297910] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/1994] [Accepted: 10/13/1994] [Indexed: 11/17/2022] Open
Abstract
In 1992, a surveillance study was performed in Canada to determine the susceptibility of nosocomial Gram-negative rods to several wide spectrum antimicrobials. Consecutive isolates from 10 institutions, as well as additional strains of selected species of Enterobacteriaceae that are known to possess the Bush group 1 beta-lactamase, were tested for susceptibility to 12 antimicrobials. Third-generation cephalosporin resistance was found to be as high as 29% in Enterobacter cloacae that possesses the Bush group 1 beta-lactamase and less than 4% in those isolates not possessing this enzyme. Cefepime equalled or exceeded the activity of the third-generation cephalosporins against the species of Enterobacteriaceae that demonstrated resistance to the third-generation cephalosporins.
Collapse
|
3
|
Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008; 9:561-75. [PMID: 18312158 DOI: 10.1517/14656566.9.4.561] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The prevalence of antibiotic-resistant bacteria continues to increase, particularly in patients in the intensive care unit with nosocomial pneumonia. The intention of this review is to provide an overview of severe nosocomial pneumonia, carbapenems and the problem of bacterial resistance to antimicrobial agents. Attention was focused on the efficacy, safety and pharmacodynamics of imipenem, meropenem, ertapenem and doripenem. Issues on the impact of appropriate empiric antibiotic therapy for nosocomial pneumonia patients considered at risk for resistant pathogens are discussed. Critical decision making regarding the use of carbapenems for treating severe nosocomial pneumonia requires careful consideration of the four Ds of optimal antimicrobial therapy: right Drug, right Dose, De-escalated to pathogen-directed therapy and right Duration of therapy.
Collapse
Affiliation(s)
- Jomy Joseph
- University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA
| | | |
Collapse
|
4
|
Schlemmer B, Jury de la conférence de consensus. Comment améliorer la qualité de l’antibiothérapie dans les établissements de soins ? Med Mal Infect 2003. [DOI: 10.1016/s0399-077x(03)00198-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Muñoz M, Márquez C, Taguas-Casaño M, Soult JA, López-Castilla JD, Alvarez-Silván AM. Resistance to a beta-lactam antibiotic appearing during therapy for enterobacter cloacae sepsis in a child. MEDICAL AND PEDIATRIC ONCOLOGY 2003; 40:62-3. [PMID: 12426691 DOI: 10.1002/mpo.10070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Miguel Muñoz
- Unidad de Cuidados Intensivos Pediátricos, Hospital Infantil Universitario Virgen del Rocio, Sevilla, Spain
| | | | | | | | | | | |
Collapse
|
6
|
Grisaru-Soen G, Lerner-Geva L, Keller N, Berger H, Passwell JH, Barzilai A. Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors. Pediatr Infect Dis J 2000; 19:959-63. [PMID: 11055596 DOI: 10.1097/00006454-200010000-00003] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To determine the factors predisposing to Pseudomonas aeruginosa bacteremia as well as the prevalence, source of infection, outcome and prognostic factors in pediatric patients. METHODS Retrospective review of pediatric patients with P. aeruginosa bacteremia, at a large tertiary care hospital during a 6.5-year period. RESULTS Seventy patients with P. aeruginosa bacteremia were identified. The annual rate of P. aeruginosa bacteremia remained unchanged during the study period. Antibiotic susceptibility remained unchanged except for two patients with extensive burns who developed resistant strains. Underlying diseases were malignancy (50%), prematurity (6%), burns (7%) and others (37%). The overall mortality associated with P. aeruginosa bacteremia was 20%. The fatality rate was higher among the young infants (compared with older children) and those who received previous antibiotic therapy (P = 0.02). Mortality rate was higher in nosocomial than in community-acquired infections (25% compared with 11.5%). The mortality rate of low birth weight and burns patients was significantly higher when compared with oncology patients or other patients, 75 and 40% compared with 11 and 19%, P = 0.01. Multiple regression analysis revealed a correlation only between the underlying disease and mortality (P = 0.02). In the oncology patients the only significant risk factor for mortality was absolute neutrophil count < or =0.1 x 10(9)/l (P = 0.06). CONCLUSION P. aeruginosa bacteremia, although apparently not increasing in incidence and antibiotic resistance, is still a common serious complication in immunocompromised children with a high mortality rate. We conclude that the underlying disease is the main determinant of the clinical outcome.
Collapse
Affiliation(s)
- G Grisaru-Soen
- Pediatric Infectious Disease Unit, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel
| | | | | | | | | | | |
Collapse
|
7
|
Ko WC, Lee HC, Chuang YC, Liu CC, Wu JJ. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia. J Infect 2000; 40:267-73. [PMID: 10908022 DOI: 10.1053/jinf.2000.0654] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
OBJECTIVES Aeromonas bacteraemia is not a common infectious disease, but can cause a grave outcome in infected cases. In this study, clinical presentations and prognostic factors of cases of monomicrobial Aeromonas bacteraemia were analysed. Also, the impact of beta-lactam and aminoglycoside in combination and of emerging cephalosporin-resistance during therapy was discussed. METHODS From 1989 to 1998 in a medical centre in southern Taiwan, those cases with monomicrobial Aeromonas bacteraemia were included for study. RESULTS A total of 104 episodes of monomicrobial Aeromonas bacteraemia, accounting for 74% of all Aeromonas bacteraemia, were encountered. The infections usually occurred in the patients with hepatic cirrhosis (54%) or malignancy (21%) and were community-acquired (74%). Cases of community-acquired bacteraemia were more likely to have cirrhosis, a high severity score at onset, and a worse prognosis than those of nosocomial bacteraemia did and nosocomial isolates were less susceptible to cefoxitin and cefotaxime. Forty-three percent of cases had a concomitant infection focus, such as primary peritonitis, invasive cellulitis or necrotizing fasciitis, biliary tract or burn wound infections. Crude fatality rate within 2 weeks after the onset was 30%. Secondary bacteraemia and a higher severity score ( > or = 4) for illness at the first presentation were independently associated with a fatal outcome. The therapeutic superiority of beta-lactam and aminoglycoside in combination cannot be demonstrated in patients with Aeromonas bacteraemia. Cefotaxime resistance emerged in 3.4% of 58 patients treated with a cephalosporin for at least 72 h. None of the community-acquired isolates, but one-quarter of the nosocomial isolates, were resistant to cefotaxime. CONCLUSIONS Aeromonas bacteraemia usually occurred in patients with liver cirrhosis or malignancy, and heralded a poor prognosis, especially while associated with a relevant infectious source or with a higher severity score at presentation. The superiority of aminoglycoside and beta-lactam in combination cannot be demonstrated while treating those patients, and the emergence of antimicrobial resistance to cephalosporin was a rare event during cephalosporin therapy. Thus, a broad-spectrum cephalosporin remains one of the antimicrobial alternatives for invasive community-acquired Aeromonas infections.
Collapse
Affiliation(s)
- W C Ko
- Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
| | | | | | | | | |
Collapse
|
8
|
Nishida K, Kunugita C, Uji T, Higashitani F, Hyodo A, Unemi N, Maiti SN, Phillips OA, Spevak P, Atchison KP, Salama SM, Atwal H, Micetich RG. In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother 1999; 43:1895-900. [PMID: 10428909 PMCID: PMC89387 DOI: 10.1128/aac.43.8.1895] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/1998] [Accepted: 05/20/1999] [Indexed: 01/25/2023] Open
Abstract
Syn2190, a monobactam derivative containing 1,5-dihydroxy-4-pyridone as the C-3 side chain, is a potent inhibitor of group 1 beta-lactamase. The concentrations of inhibitor needed to reduce the initial rate of hydrolysis of substrate by 50% for Syn2190 against these enzymes were in the range of 0.002 to 0.01 microM. These values were 220- to 850-fold lower than those of tazobactam. Syn2190 showed in vitro synergy with ceftazidime and cefpirome. This synergy was dependent on the concentration of the inhibitor against group 1 beta-lactamase-producing strains, such as Pseudomonas aeruginosa, Enterobacter cloacae, Citrobacter freundii, and Morganella morganii. However, against beta-lactamase-derepressed mutants of P. aeruginosa, the MICs of ceftazidime plus Syn2190 were not affected by the amount of beta-lactamase, and the values were the same for the parent strains. The MICs at which 50% of isolates are inhibited (MIC(50)s) of ceftazidime plus Syn2190 were 2- to 16-fold lower than those of ceftazidime alone for ceftazidime-resistant, clinically isolated gram-negative bacteria. Similarly, the MIC(50)s of cefpirome plus Syn2190 were two- to eightfold lower for cefpirome-resistant clinical isolates. The synergies of Syn2190 plus ceftazidime or cefpirome observed in vitro were also reflected in vivo. Syn2190 improved the efficacies of both cephalosporins in both a murine systemic infection model with cephalosporin-resistant rods and urinary tract infection models with cephalosporin-resistant P. aeruginosa.
Collapse
Affiliation(s)
- K Nishida
- Antimicrobial Research Laboratory, Taiho Pharmaceutical Co., Ltd. Tokushima 771-0194, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Hsueh PR, Teng LJ, Yang PC, Chen YC, Ho SW, Luh KT. Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol 1998; 36:1347-51. [PMID: 9574703 PMCID: PMC104826 DOI: 10.1128/jcm.36.5.1347-1351.1998] [Citation(s) in RCA: 97] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Long-term colonization of various body sites with a multidrug-resistant Pseudomonas aeruginosa clone (resistant to piperacillin, cefoperazone, ceftazidime, aztreonam, imipenem, cefepime, cefpirome, ofloxacin, ciprofloxacin, minocycline, and aminoglycosides) with subsequent severe infections in burn patients has not been reported previously. Thirty-nine isolates of multidrug-resistant P. aeruginosa (resistant to ceftazidime and at least three of the agents listed above) recovered from various clinical samples from three patients in an intensive care burn unit from April 1997 to May 1997 and seven preserved isolates recovered from six patients in other medical wards at National Taiwan University Hospital from April 1996 to May 1997 were studied for their epidemiological relatedness. The epidemic could be attributed to a multidrug-resistant P. aeruginosa clone belonging to serogroup O:F (serogroup O:4) by means of antimicrobial susceptibility testing, O serogrouping, and analysis of the randomly amplified polymorphic DNA patterns generated by arbitrarily primed PCR of the isolates. The epidemic strain persisted in the three patients for weeks to months; in the meantime, these patients had received multiple antimicrobial agents for the management of intervening episodes of invasive infections (bacteremia, ventilator-associated pneumonia, and/or catheter-related sepsis) caused by this strain, as well as concomitant infections due to other organisms. The strain had been isolated only once previously, from a burn patient who was on the unit in December 1996. The present report, describing a small outbreak due to P. aeruginosa, documents the fact that a single clone of multidrug-resistant P. aeruginosa can cause long-term persistence in different body sites of burn patients and that the colonization can subsequently result in various severe infections.
Collapse
Affiliation(s)
- P R Hsueh
- Department of Laboratory Medicine, National Taiwan University Hospital, Taipei
| | | | | | | | | | | |
Collapse
|
10
|
Li XZ, Zhang L, Srikumar R, Poole K. Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42:399-403. [PMID: 9527793 PMCID: PMC105421 DOI: 10.1128/aac.42.2.399] [Citation(s) in RCA: 79] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/1997] [Accepted: 12/01/1997] [Indexed: 02/07/2023] Open
Abstract
The MexAB-OprM multidrug efflux system exports a number of antimicrobial compounds, including beta-lactams. In an attempt to define more fully the range of antimicrobial compounds exported by this system, and, in particular, to determine whether beta-lactamase inhibitors were also accommodated by the MexAB-OprM pump, the influence of pump status (its presence or absence) on the intrinsic antibacterial activities of these compounds and on their abilities to enhance beta-lactam susceptibility in intact cells was assessed. MIC determinations clearly demonstrated that all three compounds tested, clavulanate, cloxacillin, and BRL42715, were accommodated by the pump. Moreover, by using beta-lactams which were readily hydrolyzed by the Pseudomonas aeruginosa class C chromosomal beta-lactamase, it was demonstrated that elimination of the mexAB-oprM-encoded efflux system greatly enhanced the abilities of cloxacillin and BRL42715 (but not clavulanate) to increase beta-lactam susceptibility. With beta-lactams which were poorly hydrolyzed, however, the inhibitors failed to enhance beta-lactam susceptibility in MexAB-OprM+ strains, although BRL42715 did enhance beta-lactam susceptibility in MexAB-OprM- strains, suggesting that even with poorly hydrolyzed beta-lactams this inhibitor was effective when it was not subjected to efflux. MexEF-OprN-overexpressing strains, but not MexCD-OprJ-overexpressing strains, also facilitated resistance to beta-lactamase inhibitors, indicating that these compounds are also substrates for the MexEF-OprN pump. These data indicate that an ability to inactivate MexAB-OprM (and like efflux systems in other bacteria) will markedly enhance the efficacies of beta-lactam-beta-lactamase inhibitor combinations in treating bacterial infections.
Collapse
Affiliation(s)
- X Z Li
- Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada
| | | | | | | |
Collapse
|
11
|
Abstract
Aztreonam is a monocyclic beta-lactam antibiotic that is active exclusively against the aerobic gram-negative bacilli. It is not ototoxic or nephrotoxic and so is used as an alternative to aminoglycosides in a variety of clinical situations. In polymicrobial infections or when used for empiric therapy, aztreonam must be combined with other antimicrobial agents active against gram-positive and anaerobic species. Aztreonam is often effective against resistant strains of gram-negative organisms, which are often involved in nosocomial infections. Overuse of aztreonam should be avoided to prevent the emergence of resistant P. aeruginosa strains. Except in the treatment of P. aeruginosa infections, aztreonam should not be added to beta-lactam regimens for additional gram-negative coverage.
Collapse
Affiliation(s)
- D H Johnson
- Infectious Disease Division, Winthrop-University Hospital, Mineola, New York, USA
| | | |
Collapse
|
12
|
Sader HS, Jones RN. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies. Eur J Clin Microbiol Infect Dis 1994; 13:675-9. [PMID: 7813503 DOI: 10.1007/bf01973999] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The in vitro activity of cefpirome against ceftazidime-resistant (MIC > 16 mg/l) isolates from two multicenter studies was analyzed. The first investigation carried out in the USA, was an in vitro comparison of cefpirome and five third-generation cephalosporins in which more than 6,000 isolates were evaluated, including 97 Enterobacteriaceae and 1,509 staphylococci resistant to ceftazidime. The second study was a multicenter international study (> 5,000 strains total) in which 160 ceftazidime-resistant gram-negative bacilli and 509 staphylococci from five countries (Australia, France, Germany, Italy and UK) were tested against cefpirome. The results from the US trial indicated that only 0.8% of enteric bacilli were resistant to cefpirome compared to 4.9% and 4.7% resistant to ceftazidime and cefoperazone, respectively. In the international trial, cefpirome was also active against ceftazidime-resistant, class I beta-lactamase producing enteric bacilli (75% susceptibility, MIC50 of 4 mg/l) especially against Citrobacter spp., Enterobacter spp. and Morganella morganii. Cefpirome was 8- to 64-fold more active than ceftazidime against seven different staphylococcal species. The antimicrobial activity of cefpirome against routine clinical isolates and those organisms resistant to third-generation cephalosporins was highly consistent within a nation (USA) and among various developed countries.
Collapse
Affiliation(s)
- H S Sader
- Department of Pathology, University of Iowa College of Medicine, Iowa City 52242
| | | |
Collapse
|
13
|
|
14
|
Routine detection of inducible ß-lactamase in gram-negative bacilli by means of disk susceptibility testing. J Microbiol Methods 1993. [DOI: 10.1016/0167-7012(93)90057-o] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
15
|
Sader HS, Jones RN. The fourth-generation cephalosporins: Antimicrobial activity and spectrum definitions using cefpirome as an example. ACTA ACUST UNITED AC 1993. [DOI: 10.1016/s0738-1751(10)80003-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
de Champs C, Henquell C, Guelon D, Sirot D, Gazuy N, Sirot J. Clinical and bacteriological study of nosocomial infections due to Enterobacter aerogenes resistant to imipenem. J Clin Microbiol 1993; 31:123-7. [PMID: 8417016 PMCID: PMC262633 DOI: 10.1128/jcm.31.1.123-127.1993] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Enterobacter aerogenes strains resistant to imipenem were isolated in 10 patients, 7 of whom had received imipenem-cilastatin. The strains were differentiated by biotype, antibiotype, and plasmid content. All of the strains overproduced a chromosomal cephalosporinase and lost a major outer membrane protein with a size of about 40 kDa. In 5 of the 10 patients, E. aerogenes strains resistant to extended-spectrum cephalosporin were isolated during the same stay. In three patients, the similarity between the imipenem-susceptible and -resistant strains suggests the occurrence of mutation and reversion in vivo. The combination imipenem-cilastatin has been critically important for use with multiresistant strains of Enterobacter spp., but its use increases the risk of selection of imipenem-resistant strains.
Collapse
Affiliation(s)
- C de Champs
- Service d'Hygiène Hospitalière, Faculté de Médecine, Clermont-Ferrand, France
| | | | | | | | | | | |
Collapse
|
17
|
Abstract
Antibiotics have dramatically changed the care of the critically ill patient over the last 60 years. Patients with complex physiological conditions present with infectious processes requiring the effective use of antimicrobial drugs. In many situations, the inability to eradicate the infectious process is complicated by the progressive development of resistance among the causative organisms. Systemic antibiotic prophylaxis is warranted only for the prevention of wound infections. Regimens in these cases should use large doses of nontoxic antibiotics covering the spectrum of organisms likely to contaminate the wound. The duration of wound prophylaxis should be short, essentially covering only the period of active wound closure; this is usually less than 24 hours. Prevention of most other infections in the ICU depends on the recognition and correction of the various disturbances of host defenses. Topical antibiotic therapy may reduce the level of colonization for a few specific types of infection. Initial empiric antibiotic therapy should be started for clear indications. The antibiotics chosen should be those most likely to be effective against the probable organisms, those which have the lowest toxicity, and those with the smallest likelihood of inducing multiresistance. They must be adjusted promptly based on the microbiologic sensitivities observed. The realization that the physiology of critical illness may alter the normal relations between drug dosages and the tissue antibiotic levels obtained mandates a different approach to the treatment of these patients. The drug volumes of distribution are generally markedly expanded in these patients. Furthermore, these patients require high tissue antibiotic concentrations to improve the chances for successful therapy. Thus, the antibiotics selected must be capable of providing these levels without significant toxicity to the host. Therapy should be continued based on the clinical response observed. Premature cessation of effective therapy often results in relapse.
Collapse
Affiliation(s)
- R L Reed
- Duke University Medical Center, Durham, North Carolina
| |
Collapse
|
18
|
Araki H, Minami S, Watanabe Y, Yasuda T. Significance of inducible cephalosporinase remaining in the experimentally infected rat granuloma pouch after beta-lactam therapy. Antimicrob Agents Chemother 1991; 35:1131-6. [PMID: 1929254 PMCID: PMC284299 DOI: 10.1128/aac.35.6.1131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
We studied the influence of inducible cephalosporinase on levels of secondarily administered beta-lactam antibiotics in exudates using experimentally infected rat granuloma pouches. Cefoperazone or cefmetazole was administered intramuscularly at a dose of 100 mg/kg of body weight to rats at 2 and 8 h after infection of rat pouches with Serratia marcescens W-24, which possesses an inducible type I beta-lactamase (cephalosporinase). Subsequently, cefotaxime or cefbuperazone was administered at an intravenous dose of 100 mg/kg to rats at 24 h postinfection. Levels of cefotaxime in the pouch exudates of the cefmetazole-pretreated group were lower than those in the control group, which was infected but not pretreated with antibiotics. This was due to the inactivation of cefotaxime by extracellular cephalosporinase which was induced by cefmetazole and which remained in the rat pouches. However, cefotaxime concentrations were not reduced in the cefoperazone-pretreated group because of the low inducibility of cefoperazone against cephalosporinase production. On the other hand, cefbuperazone concentrations were similar in all groups (control, cefoperazone pretreated, and cefmetazole pretreated), because cefbuperazone is more stable against this enzyme than cefotaxime is. In conclusion, concentrations of secondarily administered beta-lactam antibiotics are affected by inducibly produced cephalosporinase at the infection site when a good inducer like cefmetazole is administered beforehand.
Collapse
Affiliation(s)
- H Araki
- Research Laboratory, Toyama Chemical Co. Ltd., Japan
| | | | | | | |
Collapse
|
19
|
Witiak DT, Wei Y. Dioxopiperazines: chemistry and biology. PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 1990; 35:249-363. [PMID: 2290982 DOI: 10.1007/978-3-0348-7133-4_7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- D T Witiak
- Division of Medicinal Chemistry, College of Pharmacy, Ohio State University, Columbus 43210
| | | |
Collapse
|
20
|
Abstract
Bacterial evolution and the emergence of antimicrobial drug resistance continue to interfere with the successful treatment of infections by both community- and hospital-based physicians. Resistance has emerged to even the newer, most potent antimicrobial agents. Although generalizations can be made about the appropriateness of antimicrobial agents on the basis of published susceptibility patterns, significant regional, demographic, and interinstitutional variables exist that require each hospital to establish its own antibiotic data base and antibiogram. In particular, multiresistant pathogens occur infrequently in acute care community hospitals compared with tertiary care centers. Important clinical factors that promote the emergence of drug-resistant flora include prolonged therapy, the persistence of foreign bodies, sequestra, or prostheses, and the inadequate surgical debridement of necrotic tissue or abscesses. Antibiotic resistance may occur through changes in the permeability of the cell wall or outer membrane, by alteration of the antimicrobial binding or target site, and by inactivation or modification of the drug by bacterial enzymes. These mechanisms are reviewed. In particular, gram-negative beta-lactamases, methicillin-resistant staphylococci, multiresistant enterococci, and the emergence of fluoroquinolone resistance are discussed in detail.
Collapse
|
21
|
Kitzis MD, Ferré B, Coutrot A, Acar JF, Gutmann L. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria. Eur J Clin Microbiol Infect Dis 1989; 8:783-8. [PMID: 2556277 DOI: 10.1007/bf02185845] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Combinations of different beta-lactam antibiotics, including cefotaxime, with three beta-lactamase inhibitors were tested against cephalosporinase producing bacterial strains. The most significant antagonism was obtained with a combination of clavulanic acid and cefotaxime, while almost no antagonism was observed with sulbactam and tazobactam. In strains belonging to five different species there was a correlation between the levels of cephalosporinase produced after exposure to different concentrations of inhibitors and the MICs of cefotaxime combined with the same concentrations of inhibitors. It is concluded that there is little likelihood of antagonism between beta-lactam antibiotics and sulbactam or tazobactam.
Collapse
Affiliation(s)
- M D Kitzis
- Laboratoire de Microbiologie Médicale, Hôpital Saint-Joseph, Paris, France
| | | | | | | | | |
Collapse
|
22
|
Abstract
Newer beta-lactam antibiotics, notably the third generation cephalosporins (3 GC) have been designed for providing high intrinsic potency against a large variety of microorganisms. Bacterial resistance can occur however, and nowadays, clinicians are concerned by novel situations where even most recently developed compounds can be ineffective. A first situation is generated by bacteria which produce great amounts of chromosomal cephalosporinase. The resistance emerges during therapy, in hospital isolates which are classified as susceptible with conventional susceptibility testing. The prevalence of 3 GC resistance among these gram-negative rods with inducible beta-lactamase seems to increase in some institutions but the significance of susceptibility testing in this regard is doubtful. It is probably more important to note that the prevalence of gram-negative rods with inducible beta-lactamases remains stable. A second problem arose with the abrupt development of plasmid mediated beta-lactamases markedly active against 3 GC. This resistance is underestimated because some strains fall into susceptibility range of 3 GC as determined by MICs or inhibition zone sizes. These extended spectrum enzymes are now distributed over four continents and represent a growing threat.
Collapse
Affiliation(s)
- J C Pechère
- University of Geneva, Department of Microbiology, Switzerland
| |
Collapse
|
23
|
|
24
|
Abstract
The introduction of gentamicin almost 20 years ago provided an effective option for the treatment of gram-negative bacillary infections. During the past few years, the availability of aztreonam (a monobactam), imipenem (a carbapenem), and newer cephalosporins within vitro activities comparable with aminoglycosides against many gram-negative bacilli, has stimulated a reassessment of the role of aminoglycosides in treating these infections. When determining the role of new antimicrobials as potential replacements for more established agents, the clinical focus should be on three factors: comparative efficacy, safety, and cost. Consideration of cost is relevant only when efficacy and safety are equivalent. Other factors, such as comparative in vitro antimicrobial activity, pharmacokinetics, and effect on normal flora can also influence the selection of an antimicrobial regimen. A new class of antimicrobials, the monobactams, is the focus of this review. The only member of this class currently in clinical use is aztreonam. A comparison with aminoglycosides is particularly relevant because aztreonam is active against aerobic gram-negative bacilli. This review will discuss the acknowledged concerns with aminoglycoside use and compare the characteristics of aztreonam and currently marketed aminoglycosides.
Collapse
Affiliation(s)
- J T DiPiro
- University of Georgia College of Pharmacy, Athens
| | | |
Collapse
|
25
|
Letendre ED, Turgeon PL. Production and induction of beta-lactamase during growth of Pseudomonas aeruginosa in biological fluids. Antimicrob Agents Chemother 1989; 33:776-7. [PMID: 2502067 PMCID: PMC172533 DOI: 10.1128/aac.33.5.776] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
beta-Lactamase production in biological fluids was evaluated by using an antibiotic-resistant Pseudomonas aeruginosa strain. Enzyme production was low in plasma or ascitic fluid and high in urine. Induction of beta-lactamase by imipenem was studied by using an inducible P. aeruginosa strain. Induction was lower in biological fluids than in Mueller-Hinton broth.
Collapse
Affiliation(s)
- E D Letendre
- Division of Microbiology and Infectious Diseases, Hôpital Saint-Luc, Montreal, Quebec, Canada
| | | |
Collapse
|
26
|
THORE MAGNUS, JALAKAS KIRSTI, ERIKSSON INGE, DORNBUSCH KATHRINE. Evaluation of a disk approximation test of inducible beta-lactamases inEnterobacteriacaeandPseudomonas aeruginosa. APMIS 1989. [DOI: 10.1111/j.1699-0463.1989.tb00794.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Sanders CC, Gates ML, Sanders WE. Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1988; 32:1893-5. [PMID: 3149885 PMCID: PMC176040 DOI: 10.1128/aac.32.12.1893] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Expression of chromosomal beta-lactamase was examined in 85 clinical isolates of Pseudomonas aeruginosa. beta-Lactamase assays with and without cefoxitin induction revealed four phenotypes of enzyme expression: low basal, inducible; moderate basal, inducible; moderate basal, constitutive; and high basal, constitutive. The isoelectric points of the major beta-lactamase bands were 9.4, 9.2, and 8.4. These results indicate that there is a limited heterogeneity in expression of chromosomal beta-lactamase of P. aeruginosa.
Collapse
Affiliation(s)
- C C Sanders
- Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178
| | | | | |
Collapse
|
28
|
Yourassowsky E, van der Linden MP, Lismont MJ, Crokaert F, Glupczynski Y. Protective effect of amdinocillin against emergence of resistance to ceftazidime in Enterobacter cloacae. Antimicrob Agents Chemother 1988; 32:1632-5. [PMID: 3075433 PMCID: PMC175942 DOI: 10.1128/aac.32.11.1632] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Enterobacter cloacae infections have been shown clinically to respond less reliably to monotherapy with broad-spectrum cephalosporins than was initially expected. Selection of populations producing high levels of beta-lactamase has been shown to be the most frequent reason for treatment failure, and the use of these agents with another active antibiotic is recommended. In this study, E. cloacae strains from clinical specimens susceptible to ceftazidime and amdinocillin by broth dilution and disk tests were examined. In the presence of ceftazidime at 10 micrograms/ml, in vitro selection of resistant organisms was demonstrated for 3 of 11 strains. Selection was prevented when amdinocillin was added in combination. A more rapid killing was also demonstrated with this combination. At inocula of 10(8) CFU/ml, ceftazidime-resistant populations were isolated from 6 of 11 strains in vitro, and the emergence of this resistance was prevented by amdinocillin. The enhanced killing effect noted for amdinocillin with ceftazidime may have resulted in part from complementary activity of the antibiotics on penicillin-binding proteins. The ceftazidime-amdinocillin combination offers an interesting prospect for the therapy of infections caused by E. cloacae strains which are initially susceptible to both antibiotics.
Collapse
Affiliation(s)
- E Yourassowsky
- Department of Microbiology, Brugmann University Hospital, Brussels, Belgium
| | | | | | | | | |
Collapse
|
29
|
|
30
|
Medeiros A. Selection de mutants resistants, developpement de la resistance in vivo et echec therapeutique. Med Mal Infect 1988. [DOI: 10.1016/s0399-077x(88)80351-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Regnier B. Strategie antibiotique des infections a bacilles a Gram negatif. Med Mal Infect 1988. [DOI: 10.1016/s0399-077x(88)80353-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Varaldo PE, Biavasco F, Mannelli S, Pompei R, Proietti A. Distribution and antibiotic susceptibility of extraintestinal clinical isolates of Klebsiella, Enterobacter and Serratia species. Eur J Clin Microbiol Infect Dis 1988; 7:495-500. [PMID: 3141156 DOI: 10.1007/bf01962599] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A total of 451 extraintestinal, clinically relevant strains of the Klebsiella, Enterobacter and Serratia spp. isolated over a nine-month period from hospitalized patients at four different centers in Italy were investigated. Identification using the API 20E system showed that isolates belonged to 12 different species. Overall, strains of Klebsiella, Enterobacter and Serratia were in a ratio of approximately 3.4:2:1. Fifty-nine per cent of all strains were from urinary specimens, 12% from respiratory secretions, 10% from wounds and abscesses, and lower percentages from other sources. All strains were tested for their susceptibility to ten antibiotics. The rate of resistance to most drugs was generally greater in Enterobacter and Serratia than in Klebsiella. The overall incidence of strains of the intermediate category (i.e. between full sensitivity and resistance) was unexpectedly high. Both the relative frequency and the antibiotic susceptibility of strains of the various species varied from center to center; possible reasons for such differences are examined.
Collapse
Affiliation(s)
- P E Varaldo
- Institute of Microbiology, University of Ancona Medical School, Italy
| | | | | | | | | |
Collapse
|
33
|
Abstract
There are several areas in which the use of aztreonam seems logical. Infections caused by organisms sensitive to aztreonam that are known to be multiresistant to other agents can be treated directly with aztreonam in single, directed therapy, thus making the use of more toxic agents unnecessary. In types of infection in which both gram positive and gram negative bacteria are present, aztreonam can replace the usual aminoglycoside component of the therapeutic regimen. In settings of mixed infections suspected of being caused by drug-resistant strains of Enterobacteriaceae and/or P. aeruginosa, aztreonam can be combined with an agent active against gram positive organisms or with one active against anaerobes. Aztreonam has proven to be effective, safe therapy for serious and life-threatening infections caused by multiresistant aerobic gram negative bacteria. It should be used in combination with drugs that inhibit gram positive species if the etiology of the infection is not known, particularly in the immunocompromised, neutropenic patient. Doses of 1 g every 8 to 12 hours will be adequate for treatment of infections caused by most Enterobacteriaceae. Whether 2 g doses every 8 hours would be preferred for treatment of systemic Pseudomonas infections remains to be determined. Urinary infections caused by gram negative bacteria can be treated with 500 mg administered IM once or twice daily. The dosage of aztreonam should be adjusted in patients with renal failure. Clearly, aztreonam is a useful addition to the antimicrobial agents available to the physician.
Collapse
Affiliation(s)
- H C Neu
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York
| |
Collapse
|
34
|
Abstract
When antibiotic combinations are used to provide a broader spectrum of antimicrobial activity or in an attempt to prevent the emergence of resistant organisms, it is rarely necessary or practical to perform tests of drug interactions in vitro. In vitro testing of combinations may be useful when combinations are used in an attempt to attain synergistic interactions. In some cases, screening methods can be used as substitutes for formal synergy testing. This paper examines the mechanisms of antibiotic interaction leading to synergism or antagonism, surveys attempts to correlate in vitro observations with efficacy in animal models, and reviews clinical data providing evidence for or against a useful role of synergistic antibiotic interactions in the treatment of human infections.
Collapse
Affiliation(s)
- G M Eliopoulos
- Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215
| | | |
Collapse
|
35
|
Abstract
The availability of beta-lactam antibiotics with extended spectra of activity against organisms commonly seen in surgical infections suggests that aminoglycoside-based therapy is no longer needed for most such community-acquired infections. The primary problems with specific beta-lactams are lack of activity against Bacteroides species and variable activity against Pseudomonas aeruginosa and enterococci. The pharmacokinetic properties of the newer beta-lactams vary considerably. This variation suggests specific settings in which these properties may be taken advantage of to improve clinical outcome.
Collapse
Affiliation(s)
- J S Solomkin
- Department of Surgery, University of Cincinnati College of Medicine, Ohio
| |
Collapse
|